Document Detail

Increasing p53 protein sensitizes non-small cell lung cancer to paclitaxel and cisplatin in vitro.
MedLine Citation:
PMID:  20944137     Owner:  NLM     Status:  MEDLINE    
AIM: To determine whether increasing p53 protein levels confers enhanced chemosensitivity in non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: Three NSCLC cell lines, with different endogenous p53 expression, were transfected with wild-type p53 (wt-p53) or CD-1 (truncated wt-p53) genes. Cells were subsequently treated with cisplatin (CDDP) or paclitaxel (PAX). Cell viability was measured using Alamar Blue Assay. RESULTS: Cells transfected with CD-1 expressed 13-38% higher levels of p53 protein compared to cells transfected with the wt-p53 gene, despite their baseline endogenous levels. CD-1-transfected cells also had higher cell death when treated with CDDP (p<0.05) or PAX, exhibiting 30-60% higher death rates than cells transfected with the wt-p53 gene and 130-160% higher than untransfected cells. A significant positive correlation between p53 protein concentration and cytotoxic response was demonstrated (R(2) for CDDP=0.823; R(2) for PAX=0.909; p<0.001). CONCLUSION: Increasing intracellular p53 protein concentrations can augment the effect of CDDP and PAX in NSCLC, despite the baseline level of p53 protein expression.
Vamsi P Guntur; J Clifford Waldrep; Jennifer J Guo; Kim Selting; Rajiv Dhand
Related Documents :
15529177 - Promyelocytic leukemia protein-induced growth suppression and cell death in liver cance...
14693837 - Analysis of cell cycle regulator proteins in non-small cell lung cancer.
9659517 - Isolation and characterisation of radioresistant human kb carcinoma cells in vitro.
7915517 - Transcriptional regulation of the pcna promoter by p53.
18634577 - No pun intended: future directions in invertebrate glial cell migration studies.
17093407 - A protein interaction network for pluripotency of embryonic stem cells.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Anticancer research     Volume:  30     ISSN:  1791-7530     ISO Abbreviation:  Anticancer Res.     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-10-14     Completed Date:  2010-11-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8102988     Medline TA:  Anticancer Res     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  3557-64     Citation Subset:  IM    
Division of Pulmonary, Critical Care, and Environmental Medicine, School of Medicine, University of Missouri, Five Hospital Drive, Columbia, MO 65212, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / pharmacology*
Blotting, Western
Carcinoma, Non-Small-Cell Lung / genetics,  metabolism*
Cell Line, Tumor
Cell Survival / drug effects
Cisplatin / pharmacology
Drug Resistance, Neoplasm / genetics*
Enzyme-Linked Immunosorbent Assay
Lung Neoplasms / genetics,  metabolism*
Paclitaxel / pharmacology
Tumor Suppressor Protein p53 / genetics,  metabolism*
Reg. No./Substance:
0/Antineoplastic Agents; 0/Tumor Suppressor Protein p53; 15663-27-1/Cisplatin; 33069-62-4/Paclitaxel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Houttuynia cordata Thunb Extract Inhibits Cell Growth and Induces Apoptosis in Human Primary Colorec...
Next Document:  Inhibition of Heat-shock Protein 27 Expression Eliminates Drug Resistance of Osteosarcoma to Zoledro...